SEARCH

SEARCH BY CITATION

References

  • 1
    Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral® Renal Transplantation Study Group. Transplantation 1996; 62: 17441752.
  • 2
    Meier-Kriesche H-U, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with Sandimmune. Am J Transplant 2002; 2: 100104.
  • 3
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS, the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977983.
  • 4
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 11101115.
  • 5
    US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296303.
  • 6
    Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet 2000; 356: 194202.
  • 7
    Vincenti F, Kirkman R, Light S et al. Interleukin 2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161165.
  • 8
    Kahan BD, Rajagopalan PR, Hall M, for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276284.
  • 9
    Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 2937.
  • 10
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States 1988–1996. N Engl J Med 2000; 342: 605612.
  • 11
    Kirk AD, Hale DA, Hoffmann SC et al. Results from a human tolerance trial using campath-1H with and without infliximab (abstract #958). Am J Transplant 2002; 2 (Suppl. 3): 378.
  • 12
    Knechtle SJ, Pirsch JD, Becker BN et al. Campath-1H induction plus rapamycin monotherapy in renal transplantation (abstract #1276). Am J Transplant 2002; 2 (Suppl. 3): 459.
  • 13
    Vieira CA, Agarwal A, Book BK et al. Rituxan for reduction of anti-HLA antibodies in patients awaiting renal transplantation (abstract #870). Am J Transplant 2002; 2 (Suppl. 3): 356.
  • 14
    Norman DJ, Vincenti F, DeMattos AM et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70: 17071712.
  • 15
    Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68: 16321637.
  • 16
    Woodle ES, Xu D, Zivlin RA et al. Phase I trial of a humanized, Fc receptor nonbonding OKT3 antibody, huOKT3gamma1 (ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68: 608616.
  • 17
    Kirk AD, Knechtle SJ, Sollinger HW, Vincenti FG, Stecher S, Nadeau K. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation (abstract #223). Am J Transplant 2001; 1 (Suppl. 1): 190.
  • 18
    Thomas ML. The leukocyte common antigen family. Ann Rev Immunol 1989; 7: 339369.
  • 19
    Basadonna G, Auersvald L, Khuong C et al. Antibody mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci USA 1998; 95: 38213826.
  • 20
    Lazarovits A, Poppema S, Zhang Z et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996; 380: 717720.
  • 21
    Rothstein DM, Basadonna GP. Anti-CD45: a new approach towards tolerance induction. Graft 1999;2: 239245.
  • 22
    Samela K, Wrammer L, Ekberg H et al. A randomized multicenter trial of the anti-ICAL-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999; 67: 729736.
  • 23
    Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990; 75: 10371050.
  • 24
    Nakakura EK, Shorthouse RA, Zheng B, McCabe SM, Jardieu PM, Morris RE. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation 1996; 62: 547552.
  • 25
    Vincenti F, Mendez R, Rajagopalan PR et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation (abstract #562). Am J Transplant 2001; 1 (Suppl. 1): 276.
  • 26
    Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 448: 18131821.
  • 27
    Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225252.
  • 28
    Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434438.
  • 29
    Özkaynak E, Gao W, Shemmeri N et al. Importance of ICOS-B7RP-I costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591596.
  • 30
    Hausen B, Klupp J, Christinas U et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001; 72: 11281137.
  • 31
    Dumont FJ. Immunosuppressive strategies for prevention of transplant rejection. Expert Opin Ther Patents 2001; 11: 377404.
  • 32
    Thomis CD, Berg JL. Peripheral expression of JAK3 is required to maintain T lymphocyte function. J Exp Med 1997; 185: 197206.
  • 33
    Noguchi MH, Yi HM, Rosenblatt AH et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147157.
  • 34
    Schorlemmer H, Bartlett R, Kurrle R. Malononitrilamides: a new strategy of immunosuppression for allo- and xenotransplantation. Transplant Proc 1998; 30: 884890.
  • 35
    Brinkmann V, Pincshewer D, Feng L, Chen S. FTY720: altered lymphocyte traffic results in allograft protection (review). Transplantation 2001; 72: 764769.
  • 36
    Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346349.
  • 37
    Chen S, Garcia GE, Liao R, Brinkmann V, Feng L. Identification of EDG-6 as a target of FTY720, a novel transplantation drug. Am J Transplant 2001; 1 (Suppl.): 456.
  • 38
    Budde K, Schmouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 10731083.
  • 39
    Skerjanec A, Hsu CH, Pellet P, Chodoff L, Schmoouder R, Sablinski T. Systemic exposure and preliminary efficacy of FTY720 in de novo renal transplant recipients (abstract #964). Am J Transplant 2002; 2 (Suppl. 3): 380.
  • 40
    Lorber M, Tedeso-Silva H, Felipe CR et al. FTY720, RAD and corticosteroids for the prevention of graft loss and acute rejection in renal allograft recipients at increased risk of delayed graft function (abstract #962). Am J Transplant 2002; 2 (Suppl. 3): 380.
  • 41
    Cascieri MA, Springer MS. The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curr Opin Chem Biol 2000; 4: 420427.
  • 42
    Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12: 511516.
  • 43
    Koga S, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine mig. J Immunol 1999; 163: 48784885.
  • 44
    Gao W, Faia KL, Csizmadia V et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 11991205.
  • 45
    Luttichou HR, Schwartz TW. Validation of chemokine receptors as drug targets. Curr Opin Drug Discov Devel 2000; 3: 610623.
  • 46
    Nelson PJ, Krensky A. Chemokines and allograft rejection: narrowing the list of suspects. Transplantation 2001; 72: 11951197.